Exosomal markers (CD63 and CD9) expression and their prognostic significance using immunohistochemistry in patients with pancreatic ductal adenocarcinoma
Author(s) -
Moh’d Khushman,
Girijesh Kumar Patel,
Javier A. Laurini,
Arun Bhardwaj,
Kelly Roveda,
Robert Donnell,
Kelley Sherling,
Brittany Case,
Arthur E. Frankel,
Sachin Gopalkrishna Pai,
William R. Taylor,
Marcus Tan,
Meir Mizrahi,
Cindy Nelson,
Mary Wyatt,
Mary C. Patton,
Steven McClellan,
Seema Singh,
Bin Wang,
Ajay P. Singh
Publication year - 2019
Publication title -
journal of gastrointestinal oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.084
H-Index - 39
eISSN - 2219-679X
pISSN - 2078-6891
DOI - 10.21037/jgo.2018.07.02
Subject(s) - cd63 , immunohistochemistry , medicine , pancreatic ductal adenocarcinoma , microvesicles , pancreatic cancer , metastasis , clinical significance , oncology , pathology , tissue microarray , tumor progression , cancer , cancer research , microrna , biology , gene , biochemistry
Exosomes are important mediators of intercellular communications and play pivotal roles in cancer progression, metastasis and chemoresistance. CD63 and CD9 are widely accepted exosomal markers. In patients with pancreatic ductal adenocarcinoma (PDAC), positive correlation between CD9 expression and overall survival (OS) was reported. CD63 expression was conserved in all patients with no reported prognostic significance. This study explored the prognostic significance of CD63 and CD9 expression using immunohistochemistry (IHC) in patients with PDAC of mixed racial background.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom